Matching Placebo (E2814) + LECANEMAB for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Jan 2013: Trial registered, NCT01760005

The trials

NCT01760005: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

State
Under way
Phase
Phase 2 and Phase 3
People
490 planned
Started
Dec 2012
Primary completion
Apr 2028
Arms
Matching placebo (E2814) plus lecanemab
Results
None posted
Papers
doi:10.1002/alz.70689, doi:10.1007/s00259-023-06209-0, doi:10.1016/s1474-4422(25)00024-9, doi:10.1101/2024.10.29.24316289
  1. 3 Jan 2013: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.